Maternal Thrombophilia and Placental Vascular Complications

Pregnancy places extraordinary demands on a woman's haemostatic system, with the coagulation cascade adapting to protect against peripartum haemorrhage. Maternal thrombophilia, a group of conditions characterised by an increased tendency to form blood clots, can disrupt this delicate balance and contribute to serious placental vascular complications. The relationship between inherited or acquired clotting disorders and adverse pregnancy outcomes—including pre-eclampsia, intrauterine growth restriction, placental abruption, and recurrent pregnancy loss—has been the focus of intense clinical research for over two decades.

In Australian maternity services, awareness of these associations shapes how obstetricians and midwives investigate adverse pregnancy outcomes. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) provides guidance on screening women with a personal or family history of thromboembolic disease or specific obstetric complications. Understanding which women warrant investigation, and which interventions genuinely improve outcomes, remains a daily clinical challenge in tertiary centres across Sydney, Melbourne, Brisbane, and Perth.

Understanding maternal thrombophilia: mechanisms and inheritance

Thrombophilias are broadly categorised as inherited or acquired. The inherited group includes Factor V Leiden mutation, prothrombin gene mutation (G20210A), and deficiencies of the natural anticoagulants protein C, protein S, and antithrombin. Factor V Leiden, the most common inherited thrombophilia in people of European descent, confers resistance to activated protein C and is found in roughly five per cent of Australians of Anglo-Celtic background. The prothrombin gene mutation is less common but clinically significant, particularly when combined with other risk factors such as obesity or smoking.

Acquired thrombophilia is dominated by antiphospholipid syndrome (APS), an autoimmune condition characterised by the presence of lupus anticoagulant, anticardiolipin antibodies, or anti-beta-2 glycoprotein I antibodies. APS is associated with a particularly high risk of placental thrombosis and is a leading identifiable cause of recurrent pregnancy loss. Diagnostic criteria, established through international consensus, require both clinical events (such as thrombosis or pregnancy morbidity) and persistent positive laboratory testing on two occasions at least twelve weeks apart.

The placenta as a vascular interface

The placenta functions as a unique vascular organ, reliant on adequate trophoblast invasion and remodelling of the maternal spiral arteries early in pregnancy. When this remodelling is incomplete, the resulting high-resistance, low-flow circulation predisposes to ischaemia-reperfusion injury, oxidative stress, and a procoagulant state within the intervillous space. In women with underlying thrombophilia, microthrombi formation within the placental vasculature compounds these problems, contributing to infarction and impaired nutrient exchange.

Clinical research presented at perinatal congresses has increasingly emphasised the overlap between thrombophilia-driven placental disease and hypertensive disorders of pregnancy. The connection between disordered placentation and pre-eclampsia, in particular, has spurred interest in early risk stratification and intervention. Discussions of Preeclampsia pathophysiology and emerging treatments at international meetings highlight how angiogenic imbalance, endothelial dysfunction, and immunological maladaptation intersect with maternal coagulation profiles.

Placental histopathology often reveals characteristic features in these cases, including distal villous hypoplasia, accelerated villous maturation, and increased perivillous fibrin deposition. While these findings are not specific, their presence in the context of an appropriate clinical history strengthens the case for postpartum thrombophilia screening.

Diagnostic pathways in Australian maternity care

Deciding whom to test represents one of the most contentious areas of obstetric haematology. RANZCOG recommends targeted rather than universal screening, focusing on women with a personal history of venous thromboembolism, recurrent pregnancy loss (defined as three or more consecutive losses before ten weeks, or one or more losses after ten weeks), severe or early-onset pre-eclampsia, placental abruption, or a family history of thrombophilia. Testing typically occurs at least six weeks postpartum, as pregnancy itself alters many coagulation parameters.

In tertiary maternity units such as the Royal Women's Hospital in Melbourne or the Mater Mothers' Hospital in Brisbane, multidisciplinary clinics bring together obstetricians, haematologists, and maternal-fetal medicine subspecialists to coordinate complex care. Medicare rebates cover most standard thrombophilia screening tests, though some specialised assays require private pathology referral. Communication between clinicians is vital, as interpretation of borderline results—such as mildly reduced protein S activity—requires careful clinical correlation.

Counselling women about test results demands sensitivity, particularly when findings are of uncertain clinical significance. Many obstetricians discuss results in terms of relative rather than absolute risk, helping families understand that thrombophilia is one of several contributing factors to adverse outcomes. Patient information materials in languages other than English remain a priority in multicultural Australian communities. Community organisations, from religious institutions to cultural associations, contribute to health literacy in ways that mainstream services cannot; even publications focused on seemingly unrelated topics, such as explorations of Jewish artistic traditions, reflect the broader cultural networks through which women seek and share health information.

Prevention strategies and anticoagulation

For women with confirmed antiphospholipid syndrome or previous thromboembolism, the cornerstone of prevention is low molecular weight heparin (LMWH) commenced early in pregnancy, often combined with low-dose aspirin. The evidence base for LMWH in women with inherited thrombophilia and adverse pregnancy outcomes is more nuanced, with randomised trials producing inconsistent results. Current Australian practice generally reserves therapeutic anticoagulation for women with the strongest indications, while considering prophylactic dosing for those with less severe phenotypes.

Aspirin has emerged as a remarkably cost-effective intervention for reducing the risk of early-onset pre-eclampsia when commenced before sixteen weeks of gestation. The ASPRE trial and subsequent meta-analyses demonstrated that 150 mg of aspirin nightly reduces pre-eclampsia risk by over sixty per cent in high-risk women identified through first-trimester combined screening. Many Australian obstetricians now incorporate this strategy into routine antenatal care, particularly for women with chronic hypertension, renal disease, or previous pre-eclampsia.

Postnatal management is equally important, as the postpartum period carries the highest daily risk of venous thromboembolism. Women with thrombophilia require extended thromboprophylaxis for at least ten days, and often six weeks, following delivery. Liaison with general practitioners, who often coordinate care after hospital discharge, ensures continuity of prophylaxis during this vulnerable window. Patient education increasingly uses multimedia approaches, and b-side cultural projects illustrate how creative storytelling can complement clinical counselling for women navigating complex decisions about future pregnancies.

Research frontiers and international collaboration

The cancelled FAOPS 2020 congress, which was to be held in Tokyo alongside PREBIC AA 2020, would have showcased emerging research on placental vascular biology and maternal coagulation disorders. The Lessons learned from the cancellation of FAOPS 2020 due to COVID-19 underscored how international scientific collaboration depends on physical gatherings, virtual platforms, and sustained funding for translational research. Australian researchers at institutions including the University of Melbourne, Monash University, and the University of Sydney have continued to contribute to global understanding of these conditions.

Recent trials are exploring novel agents, including direct oral anticoagulants in selected pregnant populations, though safety data remain limited. Advances in first-trimester screening algorithms combine maternal characteristics, biophysical markers (such as mean arterial pressure and uterine artery Doppler), and biochemical analytes (PAPP-A, PlGF) to identify women at risk of placental complications with impressive accuracy.

Health economic analyses from the Australian Institute of Health and Welfare suggest that prevention-focused models of care may ultimately reduce the substantial costs associated with neonatal intensive care admission and long-term childhood morbidity.

For Australian clinicians managing women with thrombophilia, the clinical imperative is clear: combine evidence-based prevention with compassionate, culturally aware communication. Continuing professional development through RANZCOG, the Society of Obstetric Medicine of Australia and New Zealand, and international networks ensures that local practice remains aligned with global evidence. Women considering future pregnancies after a thrombophilia-related complication should be offered preconception counselling, individualised risk assessment, and access to multidisciplinary expertise. With thoughtful integration of research, clinical care, and patient partnership, outcomes for mothers and babies continue to improve across our diverse maternity services.